Dolutegravir
| Dolutegravir | |
|---|---|
 |
|
|
(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide |
|
| Identifiers | |
| CAS number | 1051375-16-6  |
| ChemSpider | 25051637 |
| ChEMBL | CHEMBL1229211 , CHEMBL1213165 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C20H19F2N3O5 |
| Molar mass | 419.38 g mol−1 |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Dolutegravir[1] is an experimental new drug under investigation for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Also known as S/GSK1349572 or just "572", the drug is under development by GlaxoSmithKline (GSK). Studies have shown dolutegravir to be effective in patients with resistance to the integrase inhibitor, raltegravir.[2] Clinical trials are underway to support dolutegravir in combination with abacavir and lamivudine, in a new new fixed dose combination called 572-Trii.[3] In February, 2013 the Food and Drug Administration announced that it would fast track dolutegravir's approval process.[4]
Results from the 96-week comparison with efavirenz, SPRING-1, showed dolutegravir 50mg orally to be effective at reducing HIV viral load and raising CD4 counts in integrase-naive patients. [5]
References [edit]
- ^ [1] American Medical Association (AMA), STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL (Dolutegravir) Accessed 3 December 2011.
- ^ Dolutegravir ("572") Holds Up in Heavily Raltegravir-Resistant Patients, Phase 2B Study Finds Nelson Vergel. The Body PRO. Accessed 23 April 2011.
- ^ Shionogi-ViiV Healthcare Starts Phase 3 Trial for "572-Trii" Test positive airwave. The Body PRO. Accessed 23 April 2011.
- ^ "GSK wins priority status for new HIV drug in U.S". Reuters. 16 February 2013. Retrieved 18 February 2013.
- ^ Horn, Tim. ViiV’s Dolutegravir Continues to Show Well After 96 Weeks, Versus Sustiva, for First-Time Treatment. AIDSmeds.com 7 Mar 2012. Accessed 14 Mar 2012.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
